113 related articles for article (PubMed ID: 1781182)
21. Psoralens percutaneous permeation across the human whole skin and the epidermis in respect to their polarity (in vitro study).
Saïd A; Makki S; Muret P; Humbert P; Millet J
J Dermatol Sci; 1997 Feb; 14(2):136-44. PubMed ID: 9039977
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of skin phototoxicity study using SD rats by transdermal and oral administration.
Yonezawa Y; Ohsumi T; Miyashita T; Kataoka A; Hashimoto K; Nejishima H; Ogawa H
J Toxicol Sci; 2015 Dec; 40(6):667-83. PubMed ID: 26558448
[TBL] [Abstract][Full Text] [Related]
23. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo.
Pathak MA; Mosher DB; Fitzpatrick TB
Natl Cancer Inst Monogr; 1984 Dec; 66():165-73. PubMed ID: 6531024
[TBL] [Abstract][Full Text] [Related]
24. PUVA therapy for photosensitive psoriasis.
Ros AM; Wennersten G
Acta Derm Venereol; 1987; 67(6):501-5. PubMed ID: 2451375
[TBL] [Abstract][Full Text] [Related]
25. Concentration of trimethylpsoralen in blood and skin after oral administration.
Ros AM; Wennersten G; Wallin I; Ehrsson H
Photodermatol; 1988 Jun; 5(3):121-5. PubMed ID: 3174490
[TBL] [Abstract][Full Text] [Related]
26. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
[TBL] [Abstract][Full Text] [Related]
27. The relationship between 8-methoxypsoralen skin and blood levels.
Roelandts R; Van Boven M; Adriaens P; De Schryver F; Degreef H
J Invest Dermatol; 1983 Oct; 81(4):331-3. PubMed ID: 6619562
[TBL] [Abstract][Full Text] [Related]
28. PUVA therapy for polymorphous light eruptions: comparison of systemic methoxsalen and topical trioxsalen regimens and evaluation of local protective mechanisms.
Jansén CT; Karvonen J; Malmiharju T
Acta Derm Venereol; 1982; 62(4):317-20. PubMed ID: 6183864
[TBL] [Abstract][Full Text] [Related]
29. Dose-response relations in phototoxicity due to 8-methoxypsoralen and UV-A in man.
Ljunggren B; Bjellerup M; Carter DM
J Invest Dermatol; 1981 Feb; 76(2):73-5. PubMed ID: 7462679
[TBL] [Abstract][Full Text] [Related]
30. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
Nimkulrat P; Leenutaphong V; Sudtim S
J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
[TBL] [Abstract][Full Text] [Related]
31. PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis.
Coven TR; Walters IB; Cardinale I; Krueger JG
Photodermatol Photoimmunol Photomed; 1999 Feb; 15(1):22-7. PubMed ID: 9990665
[TBL] [Abstract][Full Text] [Related]
32. Action spectra of topical psoralens: a re-evaluation.
Cripps DJ; Lowe NJ; Lerner AB
Br J Dermatol; 1982 Jul; 107(1):77-82. PubMed ID: 7104210
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo.
Halder RM; Battle EF; Smith EM
Arch Dermatol; 1995 Jun; 131(6):734-5. PubMed ID: 7778934
[No Abstract] [Full Text] [Related]
34. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
George SA; Ferguson J
Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
[TBL] [Abstract][Full Text] [Related]
35. Dietary intake and risk assessment of phototoxic furocoumarins in humans.
Schlatter J; Zimmerli B; Dick R; Panizzon R; Schlatter C
Food Chem Toxicol; 1991 Aug; 29(8):523-30. PubMed ID: 1894218
[TBL] [Abstract][Full Text] [Related]
36. Improved prediction of the minimal phototoxic dose in PUVA therapy.
Sakuntabhai A; Matthews JN; Farr PM
Br J Dermatol; 1994 May; 130(5):604-9. PubMed ID: 8204468
[TBL] [Abstract][Full Text] [Related]
37. Serum 8-methoxypsoralen (8-MOP) concentrations after bath water delivery of 8-MOP plus UVA.
David M; Lowe NJ; Halder RM; Borok M
J Am Acad Dermatol; 1990 Nov; 23(5 Pt 1):931-2. PubMed ID: 2254480
[No Abstract] [Full Text] [Related]
38. Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens.
Wamer W; Giles A; Kornhauser A
Photodermatol; 1987 Oct; 4(5):236-9. PubMed ID: 3697346
[TBL] [Abstract][Full Text] [Related]
39. Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration.
Zucchi A; Raho E; Marconi B; Nicoli S; Santini M; Allegra F; Colombo P; Bettini R; Santi P
J Invest Dermatol; 2001 Aug; 117(2):379-82. PubMed ID: 11511320
[TBL] [Abstract][Full Text] [Related]
40. 8-Methoxypsoralen serum levels in poor responders to photochemotherapy. Importance of drug formulation and individual factors.
Walther T; Haustein UF
Int J Dermatol; 1991 Jul; 30(7):516-8. PubMed ID: 1769779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
